Abstract
Background In metastatic triple negative breast cancer (mTNBC), median progression-free survival (PFS) with chemotherapy alone is approximately 2–4 months1 and improvements with single agent checkpoint inhibitors (CI) are limited by...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have